Nivolumab
Treatment for Stomach Cancer
Typical Dosage: 240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Effectiveness
60%
Safety Score
40%
Clinical Trials
104
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Time to Effect
4-12 weeks
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$140,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$155,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$380,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$1,291,667
Cost per Remission
$15,500,000
Comparison vs Placebo/Best Supportive Care
Cost Difference
+$140,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Nivolumab Outcomes
for Stomach Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+12%
Remission Rate
+1%
Common Side Effects
Fatigue
+20%
Pruritus
+10%
Diarrhea
+8%
Immune-mediated pneumonitis
+2%
Immune-mediated colitis
+1.5%
Hypothyroidism
+7%
Active Clinical Trials
6 active trials recruiting for Nivolumab in Stomach Cancer
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
NCT05334719ACTIVE NOT RECRUITING
500 participants
OBSERVATIONAL
Minato-ku, Japan
Started: Jun 29, 2022
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
NCT07149090RECRUITINGPHASE1, PHASE2
61 participants
INTERVENTIONAL
Seoul, South Korea
Started: Nov 11, 2025
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611RECRUITINGPHASE2
120 participants
INTERVENTIONAL
Angers, France +36 more
Started: Apr 16, 2024
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
NCT06008925RECRUITINGPHASE1, PHASE2
43 participants
INTERVENTIONAL
Beijing, China
Started: Nov 17, 2022
RegoNivo vs Standard of Care Chemotherapy in AGOC
NCT04879368ACTIVE NOT RECRUITINGPHASE3
450 participants
INTERVENTIONAL
Scottsdale, United States +93 more
Started: Jun 1, 2021
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328ACTIVE NOT RECRUITINGPHASE2
210 participants
INTERVENTIONAL
Nagoya, Japan +62 more
Started: Dec 6, 2023
Completed Clinical Trials
8 completed trials for Nivolumab in Stomach Cancer
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
NCT03662659COMPLETEDPHASE2
274 participants
INTERVENTIONAL
Clovis, United States +78 more
Started: Oct 16, 2018
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
NCT03409848COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Amberg, Germany +34 more
Started: Mar 1, 2018
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
NCT03453164COMPLETEDPHASE1, PHASE2
41 participants
INTERVENTIONAL
Fukushima, Japan
Started: Mar 28, 2018
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
NCT06452329COMPLETED
260 participants
OBSERVATIONAL
Wuhan, China +1 more
Started: Feb 28, 2024
A Benefit Population Atlas of nICT Versus nCT for LAGC
NCT07098104COMPLETED
291 participants
OBSERVATIONAL
Nanjing, China
Started: Nov 1, 2019
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
NCT05535569COMPLETEDPHASE1, PHASE2
50 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jul 17, 2017
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
NCT03980925COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Badalona, Spain +11 more
Started: Oct 11, 2019
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
NCT02999295COMPLETEDPHASE1, PHASE2
46 participants
INTERVENTIONAL
Tokyo, Japan
Started: Jan 1, 2017
Showing 20 of 105 total trials